Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation

Journal of Evaluation in Clinical Practice

Volumn 19, Issue 5, 2013, Pages 938-943

  Huang, Cindy ^a   Siu, Michele ^a   Vu, Lily ^a   Wong, Soo ^a   Shin, Jaekyu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dabigatran; oral anticoagulants; physician behaviour; prescribing decision; prescription; warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOLOGIST; CHADS2 SCORE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; MALE; PHYSICIAN; PRIORITY JOURNAL;

DABIGATRAN; ORAL ANTICOAGULANTS; PHYSICIAN BEHAVIOUR; PRESCRIBING DECISION; PRESCRIPTION; WARFARIN;

ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; ELIGIBILITY DETERMINATION; FEES, PHARMACEUTICAL; FEMALE; HEALTH CARE SURVEYS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; UNITED STATES; WARFARIN;

EID: 84885022750     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2012.01886.x     Document Type: Article

References (20)

1. Ezekowitz, M. D., Connolly, S., Parekh, A., Reilly, P. A., Varrone, J., Wang, S., Oldgren, J., Themeles, E., Wallentin, L., &, Yusuf, S., (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal, 157, 805-810.
2. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139-1151.
3. Stangier, J., (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetics, 47, 285-295.
4. Wallentin, L., Yusuf, S., Ezekowitz, M. D., et al. (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, 376, 975-983.
5. Food and Drug Administration (2012) Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm (last accessed 1 June 2012).
6. Topol, E., (2011) Why has dabigatran uptake been disappointing? Available at: http://www.blogs.theheart.org/topolog/2011/6/9/why-aren-t-you-prescribing- dabigatran (last accessed 1 June 2012).
7. Schumock, G. T., Walton, S. M., Park, H. Y., Nutescu, E. A., Blackburn, J. C., Finley, J. M., &, Lewis, R. K., (2004) Factors that influence prescribing decisions. Annals of Pharmacotherapy, 38, 557-562.
8. Allan, G. M., Lexchin, J., &, Wiebe, N., (2007) Physician awareness of drug cost: a systematic review. PLoS Medicine, 4, e283.
9. Mason, A., (2008) New medicines in primary care: a review of influences on general practitioner prescribing. Journal of Clinical Pharmacy and Therapeutics, 33, 1-10.
10. Chauhan, D., &, Mason, A., (2008) Factors affecting the uptake of new medicines in secondary care-a literature review. Journal of Clinical Pharmacy and Therapeutics, 33, 339-348.
11. Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., &, Turakhia, M. P., (2011) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals of Internal Medicine, 154, 1-11.
12. Kamel, H., Johnston, S. C., Easton, J. D., &, Kim, A. S., (2012) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke, 43, 881-883.
13. Shah, S. V., &, Gage, B. F., (2011) Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation, 123, 2562-2570.
14. Ljungberg, C., Lindblad, A. K., &, Tully, M. P., (2007) Hospital doctors' views of factors influencing their prescribing. Journal of Evaluation in Clinical Practice, 13, 765-771.
15. You, J. J., Singer, D. E., Howard, P. A., et al. (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141, e531S-e575S.
16. Prosser, H., Almond, S., &, Walley, T., (2003) Influences on GPs' decision to prescribe new drugs-the importance of who says what. Family Practice, 20, 61-68.
17. Bradley, C. P., (1992) Factors which influence the decision whether or not to prescribe: the dilemma facing general practitioners. British Journal of General Practice, 42, 454-458.
18. Nutescu, E. A., Park, H. Y., Walton, S. M., Blackburn, J. C., Finley, J. M., Lewis, R. K., &, Schumock, G. T., (2005) Factors that influence prescribing within a therapeutic drug class. Journal of Evaluation in Clinical Practice, 11, 357-365.
19. Kaakeh, R., Sweet, B. V., Reilly, C., Bush, C., DeLoach, S., Higgins, B., Clark, A. M., &, Stevenson, J., (2011) Impact of drug shortages on U.S. health systems. American Journal of Health-System Pharmacy, 68, 1811-1819.
20. Wittkowsky, A. K., (2011) Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy, 31, 1175-1191.